Survival trends: pancreatic cancer in the USA

survival trends: pancreatic cancer in the USA STUDY BACKGROUND  Pancreatic cancer (PC) is a devastating malignancy with a 5-year survival rate of 10%. Despite accounting for only 3% of all new cancer diagnoses, it is the third leading cause of cancer-related deaths in the US. Surgical resection is the only potentially curative

Osteopenia predicts outcomes in pancreatic cancer

Osteopenia predicts outcomes in pancreatic cancer Study Background Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer deaths in the United States and is projected to become the second by 2030. The unfavorable prognosis of PDAC can be attributed to late diagnosis, poor metabolic status, and the resistance of cancer

Pseudouveitis with pancreatic carcinoma: a case study

Pseudouveitis with pancreatic carcinoma: a case study Overview of the Study  This study is a report of a case of a 61- year- old man who presented with progressive deterioration of general condition with unilateral recurrent episodes of pseudouveitis presenting as non- granulomatous panuveitis of the left eye related to a choroidal

Genetic Mutations for Predicting Pancreatic Ductal Adenocarcinoma Susceptibility

Genetic Mutations for Predicting Pancreatic Ductal Adenocarcinoma Susceptibility Pancreatic ductal adenocarcinoma (PDAC) is the deadliest malignancy representing about 90% of all pancreatic cancers. PDAC progresses asymptomatically until death and is refractory to most treatment methods. Surgery is the most effective treatment. Nevertheless, it is well known that only 15-20% of PDAC

Survival trends: pancreatic cancer in the USA